Compare MasTec Inc (MTZ) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Repligen Corporation Common Stock — how do they compare? MasTec Inc trades at $191 (market cap $15.62B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: MasTec Inc is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 25 Days and Repligen Corporation Common Stock for 0 Days on average.
| MTZ | RGEN | |
|---|---|---|
Market Cap | $15.62B | $11.31B |
Volume | 1,770,191 | 1,216,919 |
Sector | Industrials | Health |
52-Week High | $437.51 | $194.57 |
52-Week Low | $190.08 | $102.87 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $18.54B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $206.12, down 0.35% on the day, with a bearish technical signal despite strong analyst support. The stock shows mixed fundamentals with a P/E of 30.96 and P/S of 0.95, while recent earnings beat expectations in two of the last three quarters. The company benefits from record backlog growth and infrastructure investment cycles, particularly in power delivery and data center markets, though cash flow trends show volatility between periods.
The outlook remains positive with 89% analyst buy ratings and a $403.92 consensus price target suggesting significant upside potential. Key risks include premium valuation concerns, communications segment softness, and execution challenges in managing rapid backlog growth. Infrastructure demand drivers provide strong tailwinds, but investors should monitor cash flow improvement and margin sustainability.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
